DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,872,108 Sandage, Jr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,872,108 Sandage, Jr USOO5872.108A United States Patent (19) 11 Patent Number: 5,872,108 Sandage, Jr. et al. (45) Date of Patent: *Feb. 16, 1999 54 REDUCTION OF INFARCT VOLUME USING D’Orlando, K.J. et al. Neurological Research (1995) CITICOLINE 17:281-284. Abstract: “Effects of Citicoline on infarct volume, mortality 75 Inventors: Bobby W. Sandage, Jr.; Marc Fisher; and behavioral outcome after temporary local ischemia' by: Kenneth W. Locke, all of Lexington, Johannes Weber et al., dated: Jan. 9, 1995, European Stroke Mass. Conference, Bordeaux, France Jun. 1-3, 1995. Kogure, K., et al., Annals of Neurology, Vol. 8, No. 3, Sep. 73 Assignee: Interneuron Pharmaceuticals, Inc., 1980, pp. 278-290. Lexington, Mass. Grosset, D.G., et al., Journal of Cardiovascular Pharma cology, vol. 25, No. 5, 1995, pp. 705–709. * Notice: The term of this patent shall not extend Lo, Eng H., Neuroscience Letters, 131, (1991), pp. 17-20. beyond the expiration date of Pat. No. McCulloch, J., et al., Acta Neurochii, (1993)Suppl 5,801,160. 57: 73-79. Tuor, U.I., et al., Stroke, vol. 24, No. 3, Mar. 1993, pp. 21 Appl. No.: 603,102 452-457. 22 Filed: Feb. 20, 1996 Grotta, James, Stroke, Vo. 18, No. 1, Jan.-Feb. 1987, pp. 264-267. Related U.S. Application Data Ochiai, Chikayuki, et al., Stroke, Vo. 13, No. 6, Nov.-Dec. 1982, pp. 788–796. 63 Continuation-in-part of Ser. No. 399.262, Mar. 6, 1995, Barinaga, Science, vol. 272, May 3, 1996, pp. 664-666. abandoned. Demeurisse, G., et al., Stroke, Vol. 14, No. 1, Jan.-Feb. 1983, (51) Int. Cl. ............................................... A61K 31/70 pp. 77-81. 52 U.S. Cl. ................................................................ 514/49 Windholtz et al. (eds.), The Merck Index, 19" Ed., Merck & 58 Field of Search ................................................. 514/49 Co., Inc. Rahway, NJ, 1983, entry 2290 at p. 329. Makishima et al., “Treatment of Sensory-Neural Deafness 56) References Cited and Tinnitus with a Nucleic Acid Derivative, Arzeneimittel Forsch. Dish., 21.(9),1343-1349 (1971). U.S. PATENT DOCUMENTS Nilsson, “CDP-Choline-A Short Review.” Clin. Pharma 4,386,078 5/1983 Horrocks et al. ....................... 424/180 col. Drug Epidemiol. 2, 273-277 (1979). Phuong et al., “Nouvell Méthode de Préparation de al OTHER PUBLICATIONS Cytidine Diphosphate Choline (CDP Choline)", Bull. Soc. HCAPLUS abstract, AN 1988: 143195, Kakihana, M. et al. Chim. Fr. Pt. II., 1979(9–10), 518–519. (1988). Gannaro et al. (eds.), Remmington's Pharmaceutical Sci Longa, Zea et al., Stroke (1989) 20:84-91. ences, 18" ed., Mack Publishing Co., Easton, PA, 1990, see The Ancrod Study Investigators, Stroke (1994) pp. 867, 1014 and 1026 as marked. 25:1755-1759. Sanchez et al., “CDP-Choline:Physico-Chemical Charac Budavari et al., The Merck Index (11th Ed.) pp. 361-362, teristics,” Arzneimittel Forschung-Drug Research, 33(II), 1995. 1011-1012(1983). Rossi, M. et al., Medline Abstract 93230870 (Feb. 1993). Algate et al., “Study of the Effects of Oral Administration of Canino, V. et al., Medline Abstract 80188636 (1980). CDP-Choline on EEG Changes and Lethality Induced by Girafto, T. et al., Embasse Abstract 71026199 (1980). Epidural Compressions in the Anaethestized Cat.” Arznei Kaste, M. et al. Stroke (1994) 25:1348–1353. mittel Forschung-Drug Research, 33(II), Olney, J.W. et al. Science (1991) 254:1515–1518. 1013–1016(1983). Kinouchi, H. et al. Proc. Natl. Acad. Sci. USA (1991) 88:11158-11162. (List continued on next page.) Diener, H.C. et al. Stroke (1995) 26:30. Bell, R.D. et al. Stroke (1991) 22:80–83. Primary Examiner Marianne M. Cintins del Zoppo, G.J. et al. Seminars in Neurology (1991) 11(4): ASSistant Examiner M. Moezie 368-384. Attorney, Agent, or Firm-Gilberto M. Villacorta, Pepper The Ancrod Stroke Study Investigators, Stroke (1994) Hamilton LLP 25:1755-1759. 57 ABSTRACT Hacke, W. et al. Stroke (1995) 26:167. Ulus, I.H. et al. Brain Research (1989) 484:217-227. The invention is directed to a method of reducing the extent Altman R. et al. British Medical Journal (1994) of infarction, particularly cerebral infarction Subsequent to 3O8:81-106. cerebral ischemia, by the administration of citicoline shortly The Canadian Cooperative Study Group, New England after an ischemic episode and continuing daily treatment for Journal of Medicine (1978) 299:53–59. up to about 30 days, preferably for at least about 6 weeks. The ESPS Group, “The European Stroke Prevention Study.” The method is useful in the treatment of stroke and severe (1990) Stroke 21:1122–1130. head trauma patients and maximizes the chances for a full or Minematsu, K. et al. Cerebrovasc. Dis. (1993) 3:99-104. substantially full recovery of the patient. Schabitz, W. et al. Journal of the Neurological Sciences (1996) 138:21–25. 17 Claims, 1 Drawing Sheet 5,872,108 Page 2 OTHER PUBLICATIONS Romero et al. (V), “CDP-Choline: 6-Month Study on Toxicity in Dogs,” Arzneimiittle Forschung-Drug Agut et al.(I), “Dissimilar Effects in Acute Toxicity Studies of CDP-Choline and Choline, Arzneimittel Forschung Research, 33(II), 1038-1042(1983). Drug Research, 33(II), 1016–1018(1983). Dinsdale et al. (II), “Pharmacokinetics of ''C CDP-Cho Braso et al., “Action of CDP-Choline by Intraduodenal line.” Arzneimittel Forschung-Drug Research, 33(II), Route on Rat Cardiorespitory System.” Arzneimittel Fors 1066–1070(1983). chung-Drug Research, 33(II), 1043–1045(1983). Fernandez, “Efficacy and Safety of Oral CDP-Choline,” Agut et al. (III), “Radioactivity Incorporation into Different Arzneimittel Forschung-Drug Research, 33(II), Cerebral Phospholipids after Oral Administration of 'C 1073-1080(1983). Methyl CDP-Choline, Arzneimittel Forschung-Drug Table of Contents, Key Word Index and Preface (J.A. Ortiz) Research, 33(II), 1048–1050(1983). Introducing the Series of Papers on Cytidine Diphosphate Agut et al.(II, “Bioavailability of Methyl-'C CDP-Cho Choline, Arzneimittel Forschung-Drug Research, 33(II), line and Choline by Oral Route.” Arzneimittel Forschung 1009-1010 (1983) and preceding pages. Drug Research, 33(II), 1045-1047(1983). Cohen et al., “Decreased Brain Choline Uptake in Older Aguilar et al., “Cerebral Subcellular Distribution of Adults-An In Vivo Proton Magnetic Resonance Spectros CDP-Choline and/or its Metabolites after Oral Administra copy Study,” J. Am. Medical Association, tion of Methyl-'C CDP-Choline.” Arzneimittel Fors 274(11).902-907(1995). chung-Drug Research, 33(II), 1051–1053(1983). Fukunaga et al. (I). “Hypotensive Effects of Adenosine and Romero et al.(I), “Low-Resolution Autoradiography in Rat Adenosine Triphosphate Compared with Sodium Nitroprus Brain after Administering Labeled CDP-Choline Adminis side.” Anesthesia and Analgesia, 61(3), 273-278 (1982). tration.” Arzneimittel Forschung-Drug Research, 33(II), 1054–1056(1983). Trovarelli, G. et al., “Effect of Cytidine on the Modification Romero et al.(II), “High-Resolution Autoradiography in of Phospholipid Metabolism Induced by Ischemia', Neuro Mouse Brain 24 h after Radiolabelled CDP-Choline Admin chemical Research, vol. 12, No. 3, 1987, pp. 227-235. istration.” Arzneimittel Forschung-Drug Research, 33(II), Trovarelli, G. et al., “The Influence of Cytidine on the 1056–1058(1983). Endogenous Pool of CDP-Choline, CDP-Ethanolamine, Romero et al. (III), “High-Resolution Autoradiography in and CMP of the Rat Brain”, Neurochemical Research, vol. Mouse Brain and Cerebellum 10 days after Radiolabelled 9, No. 1, 1984, pp. 73–79. CDP-Choline Administration,” Arzneimittel Forschung Trovarelli, G. et al., “The Transport of Cytidine into Rat Drug Research, 33(II), 1058–1060(1983). Brain. In Vivo, and its Conversion into Cytidine Metabo Dinsdale et al. (I), “CDP-Choline Repeated Oral Dose lites”, Neurochemical Research, vol. 7, No. 10, 1982, pp. Tolerance Studies in Adult Healthy Volunteers,” Arzneimit 1199-12O7. tel Forschung-Drug Research, 33(II), 1061-1065 (1983). De Medio, G.E. et al., “The Effect of Cytidine-Diphosphate Arrannz et al. “Treatment of Chronic Dyskinesia with Choline (CDP-Choline) on Brain Lipid Changes During CDP-Choline, Arzneimittel Forschung-Drug Research, Aging”, Journal of Neuroscience Research, 11:49-58 33(II), 1071-1073(1983). (1984). Tornos et al. (I), “Effect of Oral CDP-Choline on Experi Petkov, V.D. et al., “Effects of Cytidine Diphosphate Cho mental Withdrawal Syndrome, Arzneimittel Forschung line on Rats with Memory Deficits”, Institute of Phisiology, Drug Research, 33(II), 1018–1021 (1983). Bulgarian Academy of Science, Sofia, Bulgaria, pp. Tornos et al. (II), “Pharmacological Study of CDP-Cho 822–828, (1993). line.” Arzneimittel Forschung-Drug Research, 33(II), Kottler, P.D. et al., “RNA Metabolism in the Rat Brain 1022–1024(1983). During Learning Following Intravenous and Intraventricular Grau et al.(I), “Study on the Protection of CDP-Choline Injections of 3H-Cytidine”, Physiology and Behavior, vol. against Nicotine Intoxification,” Arzneimittel Forschung Drug Research, 33(II), 1025-1026(1983). 8, pp. 219–297 (1992). Tornos et al. (III), “Pharmacological Study of Oral Wurtman, R.J. et al., “The Autocannibalism of CDP-Choline, Arzneimittel Forschung-Drug Research, Choline-Containing Membrane Phospholipids in the Patho 33(II), 1026–1029(1983). genesis of Alzheimer's Disease', Dept. of Applied Biologi Agut et al. (IV), “Effect of Oral CDP-Choline on Acryla cal Sciences, Cambridge, MA, USA and Pharmacology mide-induced Lesion.” Arzneimittel Forschung-Drug Department, Universite, Suisse Neurochem. Intl., pp. Research, 33(II), 1029-1033(1983). 369-372 (1985). Grau et al. (II), “CDP-Choline: Acute Toxicity Study,” Buyukuysal, R.L. et al., “4-Aminopyridine Increases Ace Arzneimittel Forschung-Drug Research, 33(II), tylcholine Release Without Diminishing Membrane Phos 1033–1034(1983). phatidylcholine”, Journal of Neurochemistry, vol. 54, No. 4, Romero et al. (IV), “Study of Subacute Toxicity of 1990, pp. 1302–1309. CDP-Choline after 30 days of Oral Administration to Savei, V. et al., “Effect of Cytidine on Membrane Phospho Rates.” Arzneimittel Forschung-Drug Research, 33(II), lipid Synthesis in Rat Striatal Slices”, Journal of Neuro 1035–1038 (1983).
Load more

Recommended publications
  • 4695389.Pdf (3.200Mb)
    Non-classical amine recognition evolved in a large clade of olfactory receptors The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Qian, Yaw Tachie-Baffour, Zhikai Liu, Maude W Baldwin, Andrew C Kruse, and Stephen D Liberles. 2015. “Non-classical amine recognition evolved in a large clade of olfactory receptors.” eLife 4 (1): e10441. doi:10.7554/eLife.10441. http://dx.doi.org/10.7554/ eLife.10441. Published Version doi:10.7554/eLife.10441 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993622 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Non-classical amine recognition evolved in a large clade of olfactory receptors Qian Li1, Yaw Tachie-Baffour1, Zhikai Liu1, Maude W Baldwin2, Andrew C Kruse3, Stephen D Liberles1* 1Department of Cell Biology, Harvard Medical School, Boston, United States; 2Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, United States; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States Abstract Biogenic amines are important signaling molecules, and the structural basis for their recognition by G Protein-Coupled Receptors (GPCRs) is well understood. Amines are also potent odors, with some activating olfactory trace amine-associated receptors (TAARs). Here, we report that teleost TAARs evolved a new way to recognize amines in a non-classical orientation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub
    US 20140314884A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub. Date: Oct. 23, 2014 (54) HEALTH SUPPLEMENT USING GUARANA A61E36/53 (2006.01) EXTRACT A613 L/455 (2006.01) (52) U.S. Cl. (71) Applicant: Shaahin Cheyene, Venice, CA (US) CPC ............... A61K 36/534 (2013.01); A61K 36/53 (2013.01); A61K 36/16 (2013.01); A61K 36/41 (72) Inventor: Shaahin Cheyene, Venice, CA (US) (2013.01); A6 IK3I/522 (2013.01); A61 K 3I/714 (2013.01); A61 K3I/455 (2013.01); (21) Appl. No.: 13/751,151 A6 IK3I/221 (2013.01); A61 K3I/685 (2013.01); A61 K3I/198 (2013.01); A61 K (22) Filed: Apr. 17, 2013 31/4375 (2013.01); A61K 31/439 (2013.01): A6 IK3I/05 (2013.01) Publication Classification USPC .......................................................... 424/745 (51) Int. Cl. (57) ABSTRACT A6 IK36/534 (2006.01) The current invention is a Supplement made from a combina A6 IK 36/6 (2006.01) tion of herbs, vitamins, amino acids which in the preferred A6 IK 36/4I (2006.01) embodiment is a 100% vegetarian liquid capsules that are A6 IK3I/522 (2006.01) ingested allow for rapid absorption. The components of the A6 IK3I/714 (2006.01) Supplement can be mint or menthol Such as peppermint or A6 IK3I/05 (2006.01) spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethy A6 IK3I/22 (2006.01) laminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum A6 IK3I/685 (2006.01) tenuiflorum, one or more teas Such as green tea, white tea or A6 IK3I/98 (2006.01) black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, A6 IK3I/4375 (2006.01) Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline A6 IK3I/439 (2006.01) (INN), Huperzine A, and Vinpocetine.
    [Show full text]
  • Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids
    Journal oj Neurochemistry Raven Press. New York 10 1985 International Society for Neurochemistry Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids Mariateresa Tacconi and Richard J. Wurtman Laboratory of Neuroendocrine Regulation, Department of Applied Biological Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A. Abstract: Phosphatidyl - N,N - dimethylethanolamine analysis of its FAs (36.9 :t 1.8 g/g). The FAs in the PE (PDME), an intermediate in the formation of phosphati- and PC of rat brain synaptosomes were also analyzed; dylcholine (PC) by the sequential methylation of phos- too little PDME was present in synaptosomes to permit phatidylethanolamine (PE), was purified from rat brain similar analysis. The percentage of unsaturated FAs in- and its fatty acid (FA) composition compared with those synaptosomal PE was even higher (43.4 vs. 27.7) than that of brain PC and PE. The proportion of polyunsaturated in PE prepared from whole brain. Since synaptosomes fatty acids (PUFAs) in the PDME (29.8%) was similar to have a very high activity of phosphatidyl-N-methyltrans- that of PE (27.7%) and much greater than in PC (2.8%). ferase, the enzyme complex that methylates PE to form Like the PUFAs of PE, the major PUFAs found in PDME PC, this enzyme may serve, in nerve endings, to produce were arachidonic acid (20:4) and docosahexaenoic acid a particular pool of PC, rich in PUFAs, which may have (22:6). An isotopic method was developed to quantify the a distinct physiological function. Key Words: Fatty PDME purified from brain; a tritiated methyl group from acid composition - Phos phatid ylethanolamine-N -meth- CHJI was transferred to the PDME in the presence of yltransferase - Phosphatidyl - N,N - dimethylethanol- cyclohexylamine to form pH]PC, and the radioactivity of amine-Rat brain.
    [Show full text]
  • Biochemical Development of Surface Activity in Mammalian Lung. IV
    Pediat. Res. 6: 81-99 (1972) Developmental physiology lung hyaline membrane disease phospholipids infants respiratory distress syndrome lecithin surfactant Biochemical Development of Surface Activity in Mammalian Lung. IV. Pulmonary Lecithin Synthesis in the Human Fetus and Newborn and Etiology of the Respiratory Distress Syndrome Louis GLUCK1391, MARIE V. KULOVIGH, ARTHUR I. EIDELMAN, LEANDRO CORDERO, AND AIDA F. KHAZIN Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, California, USA Extract The surface-active complex lining alveoli in normal lung lowers surface tension on ex- piration, thus preventing alveolar collapse. Surface activity follows a developmental timetable. Infants with idiopathic respiratory distress syndrome (RDS) almost ex- clusively are prematurely born, and their lungs lack adequate surface activity and are deficient in the principal surface-active component, lecithin. This deficiency implies that RDS is a "disease of development," with fetal and neonatal timetables for lecithin synthesis. The biosynthesis of lung lecithin in the living human infant was studied by examining phospholipids in lung effluent (pharyngeal aspirates, mucus), which have identical phospholipids to those in lung lavage (alveolar wash). The fatty acid esters of isolated lecithin and phosphatidyl dimethylethanolamine (PDME) were examined. The fi-carbon fatty acids are indicators of the primary pathways of synthesis of lecithin: (1) a preponderance of palmitic acid signifying cytidine diphosphate choline (CDP-choline) + D-a,{3-diglyceride -+lecithin (choline incorporation pathway) and (2) a preponder- ance of myristic acid signifying phosphatidyl ethanolamine (PE) + 2 CH3 —»• PDME + CHZ —> lecithin (methylation pathway). Fetal lung of 18 and 20 weeks showed slight incorporation by GDP-choline pathway, absence of PDME, and almost no methylation.
    [Show full text]
  • 1 Doctor Recommended for Ear Ringing Relief
    6/17/2019 Amazon.com: Premium Brain Function Supplement – Memory, Focus, Clarity – Nootropic Booster with DMAE, Bacopa Monnieri, L-Glutamine, Multi… Skip to main content All Try Prime brain supplement Deliver to EN Hello, Sign in 0 Guilford 06437 Today's Deals Your Amazon.com Gift Cards Account & Lists Orders Try Prime Cart ‹ Back to results Premium Brain Function Supplement – Memory, Focus, Clarity Price: $18.95 ($0.32 / Count) $19.95 $1.00 (5%) – Nootropic Booster with DMAE, Bacopa Monnieri, L- FREE Shipping on orders over $25—or get FREE Two-Day Shipping with Amazon Prime 1,425 customer reviews | 82 answered questions Extra $1.00 Off Coupon on first Subscribe and Save order only. Details In Stock. Sold by Arazo Nutrition and Fulfilled by Amazon. Subscribe & Save 5% 15% $18.95 ($0.32 / Count) Save 5% now and up to 15% on auto- deliveries. Learn more Get it Tuesday, Jun 18 One-time Purchase $19.95 ($0.33 / Count) 1+ Qty: Deliver every: 1 1 month ( Most common ) Subscribe now Add to List About the product ★ SCIENTIFICALLY FORMULATED – We carefully combined just the right amount of 41 ingredients into a premium formula designed to boost your focus, memory, concentration Other Sellers on Amazon 2 new from $19.95 and clarity. Perfect for college students, busy moms and aging seniors over 50. ★ FOCUS, MEMORY & CLARITY – Brain Plus is an all-natural Nootropic, formulated to help $22.95 ($0.38 / Count) & FREE Shipping on eligible Add to Cart support memory and cognition. The perfect blend of ingredients will increase oxygen and orders.
    [Show full text]
  • Nutritional and Herbal Therapies for Children and Adolescents
    Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians George M. Kapalka Associate Professor, Monmouth University West Long Branch, NJ and Director, Center for Behavior Modifi cation Brick, NJ AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA Copyright © 2010 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email: [email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material
    [Show full text]
  • 1 Protective Effects of L-Alpha-Glycerylphosphorylcholine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by SZTE Doktori Értekezések Repozitórium (SZTE Repository of Dissertations) Protective effects of L-alpha-glycerylphosphorylcholine on ischaemia-reperfusion- induced inflammatory reactions Tünde T őkés 1, Eszter Tuboly 1, Gabriella Varga 1, László Major 2, Miklós Ghyczy 3, József Kaszaki 1, Mihály Boros 1* 1Institute of Surgical Research, University of Szeged, Szeged, Hungary 2Department of Oral and Maxillofacial Surgery, University of Szeged, Szeged, Hungary 3Retired chemist, Cologne, Germany Corresponding author*: Name: Mihály Boros Address: University of Szeged, School of Medicine, Institute of Surgical Research, Pécsi u. 6. Szeged, H-6720, Hungary Phone: +36 62 545103 FAX: +36 62 545743 E-mail address: [email protected] TT and ET contributed equally to this work. 1 Abstract Purpose: Choline-containing dietary phospholipids, including phosphatidylcholine (PC), may function as anti-inflammatory substances, but the mechanism remains largely unknown. We investigated the effects of L-alpha-glycerylphosphorylcholine (GPC), a deacylated PC derivative, in a rodent model of small intestinal ischaemia-reperfusion (IR) injury. Methods: Anaesthetized Sprague-Dawley rats were divided into control, mesenteric IR (45 min mesenteric artery occlusion, followed by 180 min reperfusion), IR with GPC pretreatment (16.56 mg kg -1 GPC i.v., 5 min prior to ischaemia) or IR with GPC post- treatment (16.56 mg kg -1 GPC i.v., 5 min prior to reperfusion) groups. Macrohaemodynamics and microhaemodynamic parameters were measured; intestinal inflammatory markers (xanthine oxidoreductase activity, superoxide and nitrotyrosine levels) and liver ATP contents were determined. Results: The IR challenge reduced the intestinal intramural red blood cell velocity, increased the mesenteric vascular resistance, the tissue xanthine oxidoreductase activity, the superoxide production and the nitrotyrosine levels, and the ATP content of the liver was decreased.
    [Show full text]
  • Dimethylethanolamine Dmb
    DIMETHYLETHANOLAMINE DMB CAUTIONARY RESPONSE INFORMATION 4. FIRE HAZARDS 7. SHIPPING INFORMATION 4.1 Flash Point: 105°F O.C. 7.1 Grades of Purity: 99% Common Synonyms Liquid Colorless Amine odor 4.2 Flammable Limits in Air: 1.6% - 11.9% 7.2 Storage Temperature: Ambient temperature Deanol 4.3 Fire Extinguishing Agents: Small fires: 2-(Dimethylamino)ethanol 7.3 Inert Atmosphere: Currently not available dry chemical, CO2, water spray or foam; B-Dimethylaminoethyl alcohol Floats and mixes with water. 7.4 Venting: Pressure-vacuum large fires: water spray, fog or foam. N,N-Dimethyl-n-(2-hydroxyethyl) 7.5 IMO Pollution Category: D amine 4.4 Fire Extinguishing Agents Not to Be Used: Not pertinent 7.6 Ship Type: 3 KEEP PEOPLE AWAY. AVOID CONTACT WITH LIQUID AND VAPOR. 4.5 Special Hazards of Combustion 7.7 Barge Hull Type: 3 Wear self-contained positive pressure breathing apparatus Products: May contain toxic gases including ammonia (incomplete and full protective clothing. 8. HAZARD CLASSIFICATIONS Shut off ignition sources and call fire department. combustion) and NOx. Stay upwind and use water spray to ``knock down'' vapor. 4.6 Behavior in Fire: Produces gaseous 8.1 49 CFR Category: Corrosive material Notify local health and pollution control agencies. nitrogen compounds that are highly toxic 8.2 49 CFR Class: 8 Protect water intakes. and irritating. 8.3 49 CFR Package Group: II 4.7 Auto Ignition Temperature: 563°F 8.4 Marine Pollutant: No Combustible. 4.8 Electrical Hazards: Class 1; Group C Fire POISONOUS GASES ARE PRODUCED IN FIRE. 8.5 NFPA Hazard Classification: Wear self-contained positive pressure breathing apparatus 4.9 Burning Rate: Currently not available and full protective clothing.
    [Show full text]
  • Acute Toxicity Screening of Novel Ache Inhibitors Using Neuronal Networks on Microelectrode Arrays Edward W
    NeuroToxicology 22 (2001) 3±12 Acute Toxicity Screening of Novel AChE Inhibitors Using Neuronal Networks on Microelectrode Arrays Edward W. Keefer1, Scott J. Norton1, Nicholas A.J. Boyle2, Vincenzo Talesa3, Guenter W. Gross1,* 1Department of Biological Sciences, University of North Texas, Denton, TX 76203, USA 2Department of Chemistry, University of Shef®eld, Shef®eld S102TN, UK 3Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia 06100, Italy Received 14 July 2000; accepted 12 October 2000 Abstract Spontaneously active neuronal networks grown from embryonic murine frontal cortex on substrate integrated electrode arrays with 64 recording sites were used to assess acute neurobiological and toxic effects of a series of seven symmetrical, bifunctional alkylene-linked bis-thiocarbonate compounds designed to possess anticholinesterase activity. Acute functional neurotoxicity in the absence of cytotoxicity was de®ned as total collapse of spontaneous activity. All of 7 6 the compounds were characterized as mixed inhibitors of AChE, with Ki's in the 10 ±10 M range. The neuronal network assays revealed high repeatability for each compound, but surprisingly diverse effects among these closely related compounds. Six of the seven compounds produced changes in network activity at concentrations of 10±350 mM. Three of the compounds were excitatory, two were biphasic (excitatory at lower concentrations, inhibitory at higher), and one was solely inhibitory. Two of the inhibitory compounds produced irreversible inhibition of activity. Responses of cortical cultures to eserine were compared to the effects produced by the test compounds, with only one of seven providing a close match to the eserine pro®le. Matching of response patterns allows the classi®cation of new drugs according to their response similarity to well-characterized agents.
    [Show full text]
  • Final- Test Database
    This document was exported from Numbers. Each table was converted to an Excel worksheet. All other objects on each Numbers sheet were placed on separate worksheets. Please be aware that formula calculations may differ in Excel. Numbers Sheet Name Numbers Table Name Excel Worksheet Name PARTTESTR1 Table 1 PARTTESTR1 LCMS methods Table 1 LCMS methods UPLC methods Table 1 UPLC methods Test Name Test Type TAT Detection Limit Min. Sample Amnt Method Reference Tags Aerobic Plate Count -- USP Aerobic Plate Count 5 Days <10 cfu/g 10 Grams USP <2021>/GL-411, APC, TAPC Purity Aerobic Plate Count -- FDA BAM Aerobic Plate Count 5 Days <10 cfu/g 10 Grams FDA BAM/GL-410, APC, TAPC Purity Aerobic Plate Count -- AOAC Aerobic Plate Count 5 Days <10 cfu/g 10 Grams AOAC 990.12/GL-412, APC, TAPC Purity Aerobic Plate Count -- EP Aerobic Plate Count 5 Days <10 cfu/g 10 Grams EP Purified Water/GL-391, APC, TAPC Purity Ash Ash 5 Days TBD 10 Grams USP <281>/GL-588 Identity Bacillus cereus Bacillus cereus 5 Days <10 cfu/g 10 Grams GL-483 Purity Bacillus coagulans Bacillus coagulans 5 Days <10 cfu/g 10 Grams GL-471 Purity Bacillus subtilis Bacillus subtilis 5 Days <10 cfu/g 10 Grams Customer Supplied Method Purity Bulk Density Bulk Density 5 Days TBD 10 Grams USP <616>/GL-587 Identity Calories Calories 5 Days TBD 10 Grams USDA Handbook No. 74, pp. 9-11 Potency Calories from Fat Calories 5 Days TBD 10 Grams 21 CFR Part 101.9 (Calc.) Potency Calories from Saturated Fat Calories 5 Days TBD 10 Grams 21 CFR Part 101.9 (Calc.) Potency Carbohydrates Carbohydrates 5 Days TBD 10 Grams Calculation Potency Coliforms -- FDA BAM Coliforms 5 Days <10 cfu/g 10 Grams FDA BAM/GL-422 Purity Coliforms -- AOAC Coliforms 5 Days <10 cfu/g 10 Grams AOAC 991.14/GL-420 Purity Coliforms -- CMMEF Coliforms 5 Days <10 cfu/g 10 Grams CMMEF/GL-391 Purity Density of Solids Density 5 Days TBD 10 Grams USP <699> Identity Mercury (Hg) DMA 5 Days TBD 10 Grams EPA 7473/GL-585 Purity E.
    [Show full text]
  • Dimethylethanolamine 99% Version 1.0 Revision Date: 08/20/2014
    Safety Data Sheet Dimethylethanolamine 99% Version 1.0 Revision Date: 08/20/2014 SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Dimethylethanolamine 99% Product Use Descrip- : SOLVENT tion Manufacturer or supplier's details Company : Nexeo Solutions LLC Address 3 Waterway Square Place Suite 1000 Woodlands, Tx. 77380 United States of America Emergency telephone number: Health North America: 1-855-NEXEO4U (1-855-639-3648) Health International: 1-855-NEXEO4U (1-855-639-3648) Transport North America: CHEMTREC 800.424.9300 Additional Infor- : Responsible Party: Product Safety Group mation: E-Mail: [email protected] MSDS Requests: 1-855-429-2661 MSDS Requests Fax: 1-281-500-2370 Website: www.nexeosolutions.com SECTION 2. HAZARDS IDENTIFICATION GHS Classification Flammable liquids : Category 3 Acute toxicity (Oral) : Category 4 Acute toxicity : Category 3 (Inhalation) Acute toxicity (Dermal) : Category 4 Skin corrosion : Category 1B Serious eye damage : Category 1 Specific target organ tox- : Category 3 (Respiratory system) icity - single exposure GHS Label element MSDS Number: 100000003538 1 / 19 Dimethylethanolamine 99% Safety Data Sheet Dimethylethanolamine 99% Version 1.0 Revision Date: 08/20/2014 Hazard pictograms : Signal word : Danger Hazard statements : H226 Flammable liquid and vapour. H302 + H312 Harmful if swallowed or in contact with skin H314 Causes severe skin burns and eye damage. H331 Toxic if inhaled. H335 May cause respiratory irritation. Precautionary statements : Prevention: P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P233 Keep container tightly closed. P240 Ground/bond container and receiving equipment. P241 Use explosion-proof electrical/ ventilating/ lighting/ equipment. P242 Use only non-sparking tools.
    [Show full text]
  • Dimethylethanolamine (DMAE) [108-01-0] and Selected Salts
    Dimethylethanolamine (DMAE) [108-01-0] and Selected Salts and Esters DMAE Aceglutamate [3342-61-8] DMAE p-Acetamidobenzoate [281131-6] and [3635-74-3] DMAE Bitartrate [5988-51-2] DMAE Dihydrogen Phosphate [6909-62-2] DMAE Hydrochloride [2698-25-1] DMAE Orotate [1446-06-6] DMAE Succinate [10549-59-4] Centrophenoxine [3685-84-5] Centrophenoxine Orotate [27166-15-0] Meclofenoxate [51-68-3] Review of Toxicological Literature (Update) November 2002 Dimethylethanolamine (DMAE) [108-01-0] and Selected Salts and Esters DMAE Aceglutamate [3342-61-8] DMAE p-Acetamidobenzoate [281131-6] and [3635-74-3] DMAE Bitartrate [5988-51-2] DMAE Dihydrogen Phosphate [6909-62-2] DMAE Hydrochloride [2698-25-1] DMAE Orotate [1446-06-6] DMAE Succinate [10549-59-4] Centrophenoxine [3685-84-5] Centrophenoxine Orotate [27166-15-0] Meclofenoxate [51-68-3] Review of Toxicological Literature (Update) Prepared for Scott Masten, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Karen E. Haneke, M.S. Integrated Laboratory Systems, Inc. P.O. Box 13501 Research Triangle Park, North Carolina 27709 November 2002 Toxicological Summary for Dimethylethanolamine and Selected Salts and Esters 11/2002 Executive Summary Nomination Dimethylethanolamine (DMAE) was nominated by the NIEHS for toxicological characterization, including metabolism, reproductive and developmental toxicity, subchronic toxicity, carcinogenicity and mechanistic studies. The nomination is based on the potential for widespread human exposure to DMAE through its use in industrial and consumer products and an inadequate toxicological database. Studies to address potential hazards of consumer (e.g. dietary supplement) exposures, including use by pregnant women and children, and the potential for reproductive effects and carcinogenic effects are limited.
    [Show full text]